Population
Human platelets (platelet-rich plasma and washed platelets) and purified cyclooxygenase (COX) enzyme
Comparison
Novel NO-releasing furoxan derivatives of aspirin vs NO-free furazan equivalents and existing…
Design
Preclinical
Authors
Loading...
These furoxan derivatives warrant further preclinical testing; leaves open translation to human antiplatelet therapy.
Novel NO-releasing furoxan derivatives of aspirin inhibit platelet aggregation primarily via intracellular NO release, offering a potential new antiplatelet strategy.
Cena et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: